Scott Gottlieb, the FDA commissioner who will step down Friday, plans to return to the American Enterprise Institute to write about and research drug prices.
Scott Gottlieb, whose last day as commissioner of the Food and Drug Administration is Friday, plans to head back to the American Enterprise Institute to work on drug pricing issues.
Before becoming FDA commissioner in May 2017, Gottlieb was a resident fellow at the think tank, using his perch to write numerous op-eds for the Wall Street Journal and other publications. He also was a partner at a venture capital firm, held various board positions and consulting jobs for pharmaceutical and medical device companies, and worked as a hospitalist at the New York University School of Medicine.
For example, in some classes of drugs there simply are not enough products competing with one another to constrain prices, he said. Some of that is the result of “gaming” by brand-name companies to keep generics off the market, he said. But there’s also new data that shows it is taking longer to bring a second drug in a particular category to market, especially for orphan drugs, or drugs that are underdeveloped because of their limited potential for profitability.
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
Outgoing FDA chief Gottlieb raises 'concern' over Walgreens, CVS selling CBD productsOutgoing Food and Drug Administration Commissioner Scott Gottlieb told lawmakers Wednesday that he's uneasy about Walgreens' and CVS' recent decisions to start selling CBD products in their drugstores.
और पढो »
Outgoing FDA chief Scott Gottlieb gets personal about leaving 'the best job' he's ever hadAfter nearly two years at the helm of the FDA, Scott Gottlieb is resigning at the beginning of April.
और पढो »
FDA Commissioner Calls for Tighter Standard for Approval of New Opioid DrugsFDA Commissioner Scott Gottlieb is proposing that the agency take the novel step of approving new opioid painkillers only if they show comparative advantages over existing drugs.
और पढो »
Safety watchdog questions FDA's approval of Parkinson's psychosis drugA drug safety watchdog has renewed its criticism of the FDA's approval of a Parkinson's psychosis medication and is calling for stronger warnings on its label for patients and their families
और पढो »
Johnson & Johnson to Air First TV Ad for Drug That Discloses Its PriceJohnson & Johnson plans to start airing the first U.S. television commercial for a prescription drug that discloses how much it costs, a nod toward rising political pressure over prices.
और पढो »
How cutting Obamacare could help drug companies keep prices highPresident Trump has promised to take on big drug companies and drug pricing, but he’s also promised to take out Obamacare. Ali Velshi and Stephanie Ruhle break down how cutting Obamacare could help companies keep prices high. Senator Ron Wyden joins the conversation with his plans to make prescription drugs more affordable.
और पढो »
Walgreens cuts 2019 profit forecast, hit by lower drug pricesWalgreens Boots Alliance Inc shares fell 13 percent on Tuesday after the company...
और पढो »
Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. groupBiogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and...
और पढो »
Oil prices resume climb, head for weekly, monthly gains that are fueling early-year surgeOil prices resume their climb on Friday, with a Thursday slump — pinned by some analysts on President Donald Trump’s talking down of prices — proving to be a fleeting move once the market refocused attention on global efforts to keep supply in check.
और पढो »
Avenatti is heading back to court, this time in CaliforniaA week after Michael Avenatti's shocking arrest in New York, the attorney famous for representing porn star Stormy Daniels in legal battles against President Donald Trump will be back in federal court Monday to face fraud charges in California. The brash lawyer faces a hearing in the Orange County
और पढो »